In this video, David Williamson reviews some of his favorite biotech firms. Many analysts have thrown their weight behind Biogen (BIIB +0.48%) and its new BG12 drug for multiple sclerosis. However, David favors Gilead (GILD 0.56%) over Biogen since Gilead has a larger, more diverse product pipeline. Celgene (CELG +0.00%) is the No. 1 biotech in David's opinion since it also has blockbuster drugs but a PEG of less than 1.0. Amgen (AMGN +1.08%) is a big company with more products in development than most people realize. Overall, for value and future earnings potential, David likes Celgene the best.
Wall Street Backs the Wrong Biotech
By Dave Williamson – Apr 12, 2013 at 10:29PM
NASDAQ: CELG
Celgene
Are these Wall Street upgrades really deserved?
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid